SCHEMBL30241925

SCHEMBL30241925

[2H]C1CCN(c2c(F)cccc2Br)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.35
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 4/20 0.33
TSHR P16473 2/20 0.33
NPC1 O15118 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
EED O75530 2/20 0.31
MAPK8 P45983 1/20 0.31
MAPK10 P53779 1/20 0.31
CHRM5 P08912 1/20 0.31
GRM2 Q14416 1/20 0.31
CYP1A2 P05177 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30561240 0.95 LMNA (0.34) LMNARAB9ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3879922 0.87 LMNA (0.42) LMNARAB9ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL30241928 0.79 ALDH1A1 (0.40) RAB9ASMN1; SMN2L3MBTL1ALDH1A1TSHR
SCHEMBL30241913 0.79 ALDH1A1 (0.41) LMNAL3MBTL1ALDH1A1TSHRKDM4E
SCHEMBL30079023 0.78 HTR3E (0.41) TSHRKDM4ECYP1A2
SCHEMBL21448007 0.77 HRH4 (0.42) RAB9ASMN1; SMN2TSHRNPC1
SCHEMBL30241927 0.77 ALDH1A1 (0.42) LMNARAB9ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL30407583 0.75 RAB9A (0.42) LMNARAB9ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL30561234 0.75 KEAP1 (0.37) LMNARAB9ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL30783952 0.75 KMT2A (0.37) LMNAL3MBTL1ALDH1A1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192708-A1 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES IDORSIA PHARMACEUTICALS LTD (CH) 2023-06-22 US disclosed
US-11608341-B2 Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators IDORSIA PHARMACEUTICALS LTD. (CH) 2023-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192708-A1 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES C3AR1, C5AR1, C5AR2 LMNA 4231/4885RAB9A 1238/4885SMN1; SMN2 4595/4885
US-11608341-B2 Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators C5AR1, C3AR1, C5AR2 LMNA 4479/4885RAB9A 1399/4885SMN1; SMN2 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.